

PRESS RELEASE

03 July 2023 14:15:00 CEST

New US study confirms the clinical advantage of the TetraGraph system for infants and young children

The first study using a novel single-use pediatric sensor and an EMG-based portable neuromuscular monitor is published, demonstrating that TetraSens Pediatric together with TetraGraph enables reliable quantitative neuromuscular monitoring of pediatric patients at all ages and for all types of surgery

Uppsala, July 3, 2023. Senzime AB (publ) a leader in the field of peri- and post-operative patient monitoring solutions, today announced a new study validating the feasibility of TetraSens pediatric disposable sensor. The study was performed at the Nationwide Children's Hospital, Columbus, US, and evaluated Senzime's TetraGraph using the TetraSens Pediatric sensor. The study demonstrated that the TetraGraph system can be used in infants and children, even those who weigh less than 10 kilograms.

Quantitative Train-of-Four (TOF) neuromuscular monitoring has seen limited use in infants and children, primarily due to lack of adequate technology and effective equipment. The recently published study *Intraoperative electromyographic monitoring in children using a novel pediatric sensor* included 51 patients who ranged in age from 0.2 to 7.9 years and in weight from 4.2 to 36.0 kilograms. The study concludes that neuromuscular monitoring can be performed intraoperatively in pediatric patients who are less than 8 years of age using a novel commercially available EMG-based monitor (TetraGraph) with a recently developed pediatric sensor (TetraSens Pediatric).

"This is the first clinical study that validates and proves the feasibility of a pediatric and portable EMG-based neuromuscular monitoring dedicated to small children. The study confirms the clinical advantage of our pediatric solution, even on very small and delicate infants," commented Philip Siberg, CEO of Senzime.

References

Kalsotra S, Rice-Weimer J, Tobias JD. Intraoperative electromyographic monitoring in children using a novel pediatric sensor. Saudi J Anaesth 2023;17:378-82. June 2022.

For further information, please contact:

Philip Siberg, CEO of Senzime AB
Phone: +46 (0) 707 90 67 34, e-mail: philip.siberg@senzime.com

About Senzime

Senzime is a Swedish medical device company that develops, manufactures, and markets CE- and FDA-cleared patient monitoring systems. Senzime's employees worldwide are committed to the vision of a world without anesthesia- and respiratory-related complications. The company markets an innovative portfolio of solutions, including the TetraGraph® and ExSpiron® 2Xi for real-time monitoring of neuromuscular and respiratory functions, typically under and after surgery. The goal is to help eliminate in-hospital complications, and radically reduce health care costs related to surgical and high acuity procedures.

Senzime targets a market opportunity valued more than SEK 40 billion per year, and operates with sales teams in the world's leading markets. The company's shares are listed on Nasdaq Stockholm Main Market (SEZI). More information is available at senzime.com.

Attachments

[New US study confirms the clinical advantage of the TetraGraph system for infants and young children](#)